Pre-made Rinucumab benchmark antibody ( Whole mAb, anti-PDGFRB therapeutic antibody, Anti-IMF1/KOGS/IBGC4/JTK12/PDGFR/PENTT/CD140B/PDGFR1/PDGFR-1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Rinucumab biosimilar, Whole mAb, Anti-PDGFRB Antibody: Anti-IMF1/KOGS/IBGC4/JTK12/PDGFR/PENTT/CD140B/PDGFR1/PDGFR-1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Rinucumab (REGN2176) is a monoclonal antibody designed for the treatment of neovascular age-related macular degeneration.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-484-1mg	1mg	3090
GMP-Bios-ab-484-10mg	10mg	Inquiry
GMP-Bios-ab-484-100mg	100mg	Inquiry
GMP-Bios-ab-484-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Rinucumab biosimilar, Whole mAb, Anti-PDGFRB Antibody: Anti-IMF1/KOGS/IBGC4/JTK12/PDGFR/PENTT/CD140B/PDGFR1/PDGFR-1 therapeutic antibody
INN Name	Rinucumab
Target	PDGFRB
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2015
Year Recommended	2016
Companies	Regeneron Pharmaceuticals
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Wet age-related macular degeneration
Development Tech	na